COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company's Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today.
多倫多,安大略,2024年10月01日(GLOBE NEWSWIRE)——COSCIENS生物製藥公司(NASDAQ: CSCI) (TSX: CSCI)("COSCIENS"或"公司"),一家專業從事開發和商業化多樣化的化妝品、營養品和藥品組合產品的生物製藥公司,宣佈任命Pierre Labbé爲董事會成員並擔任公司審計委員會主席,自今日起生效,以填補因Dennis Turpin辭職而產生的空缺。
Mr. Labbé has more than 30 years of progressive financial leadership roles in various industries. Mr. Labbé is currently the Executive Vice-President, Finance of Fonds QScale S.E.C., which is actively developing environmentally responsible computing centers, where he oversees financial strategy, investor relations, financial reporting, tax, treasury and risk management. Prior to joining Fonds QScale S.E.C., Mr. Labbé was the Chief Financial Officer of IMV Inc. for five years. Among other positions, he also previously served as Chief Financial Officer and Corporate Secretary of LeddarTech Inc. and Medicago Inc. (TSX). In addition, Mr. Labbé has been a director of Osisko Gold Royalties Ltd. a TSX- and NYSE-listed precious metal royalty company, since 2015, and currently serves as the Chair of its Human Resources Committee and as a member of its Audit and Risk Committee. As Senior Financial Officer, Pierre has played a key role in financing and mergers and acquisitions, overseeing transactions exceeding $1 billion.
Labbe先生在各行業擁有超過30年的不斷髮展的財務領導職務。Labbe先生目前擔任QScale S.E.C.基金的執行副總裁,該基金正在積極開發環保的計算中心,在那裏他負責財務戰略、投資者關係、財務報告、稅務、資金管理和風險管理。在加入QScale S.E.C.基金之前,Labbe先生曾擔任IMV Inc.的首席財務官五年。在其他職務中,他還曾擔任LeddarTech Inc.和Medicago Inc.(TSX)的首席財務官和公司秘書。此外,Labbe先生自2015年起擔任Osisko黃金收入有限公司的董事,該公司在TSX和NYSE上市,是一家貴金屬特許權公司,並目前擔任其人力資源委員會主席和審計和風險委員會成員。作爲高級財務官,Pierre在融資和併購中發揮着關鍵作用,監督超過10億美元的交易。
"It is my pleasure to welcome Pierre to the COSCIENS board," said Chair of the Board, Ronald Miller. "His track record of results-driven leadership, strategic thinking, and financial acumen will be an asset as COSCIENS continues to pursue its strategic direction and accomplish our goals. I would also like to express our gratitude to Mr. Dennis Turpin for his many years of dedicated service and, in particular, for sharing his financial expertise with the board over those years."
"我很高興地歡迎Pierre加入COSCIENS董事會,"董事會主席羅納德·米勒說。"他的成績導向的領導力、戰略思維和財務眼光將成爲COSCIENS在繼續追求戰略方向和實現我們目標時的資產。我還要感謝Dennis Turpin先生多年來的敬業服務,特別是在這些年裏與董事會分享他的財務專業知識。"
Mr. Labbé holds a Bachelor's Degree in Business Administration and a license in accounting from Université Laval, Québec City. He is a member of the Chartered Professional Accountants of Canada, Quebec Chartered Professional Accountants Order and the Institute of Corporate Directors. He also holds the ICD.D designation from the Institute of Corporate Directors.
Labbe先生持有魁北克省拉瓦爾大學的工商管理學士學位和會計許可證。他是加拿大特許專業會計師、魁北克特許專業會計師學會和董事學院的成員。他還持有董事學院的ICD.D資格。
About COSCIENS Biopharma Inc.
關於COSCIENS生物製藥公司
COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ("AGHD"). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
COSCIENS是一家專業的生物製藥公司,致力於開發和銷售包括專注於重大醫療需求領域的藥品和診斷產品在內的多樣化產品組合。 COSCIENS的主要產品之一是馬西莫列林(Macrilen; Ghryvelin),這是首個也是唯一獲得美國FDA和歐洲藥品管理局批准用於診斷成人生長激素缺乏症("AGHD")的口服測試。 COSCIENS還致力於開發治療資產和專有的提取技術,該技術應用於從可再生植物資源中提取活性成分,目前已用於生產美容保健產品(例如燕麥β-葡聚糖和燕麥甙素,這些成分被用於領先的護膚產品品牌,如雅漾和巴特蜜的配方)並正在開發爲潛在的保健品和/或藥品。
The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol "CSCI". For more information, please visit COSCIENS' website at .
該公司在納斯達克資本市場和多倫多證券交易所上市,並在兩家交易所上以「CSCI」標的進行交易。欲了解更多信息,請訪問COSCIENS的網站 .
Forward-Looking Statements
前瞻性聲明
The information in this news release has been prepared as of October 1, 2024. Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words.
本新聞稿中的信息截至2024年10月1日已經準備好。本新聞發佈中的某些陳述,即所謂的「前瞻性陳述」,構成1995年修正的美國《證券訴訟改革法案》和《加拿大證券法》條款下的「前瞻性信息」。所有陳述,除了回顧事實的陳述之外,涉及可能發生的情況、事件、活動或發展的陳述都屬於前瞻性陳述。在本新聞中使用時,「預期」、「假設」、「相信」、「可能」、「期望」、「預測」、「未來」、「目標」、「引導」、「打算」、「可能」、「會」等詞語或其負面或可比較的術語以及通常用於未來和假設條件的詞彙通常用於識別前瞻性陳述,儘管並非所有前瞻性陳述都包含這些詞語。
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.
前瞻性聲明必須基於多個因素和假設,儘管截至聲明日公司認爲這些聲明合理,卻天然受到重大的業務、經濟、運營和其他風險、不確定性、偶發事項和其他因素的影響,包括以下因素,因此不應過度依賴這些聲明。這些風險和不確定性包括但不限於:合併後公司的現有和未來業務戰略;運營人績在預期範圍內;預期未來現金流;合併後公司所處的當地和全球經濟情況和環境;預期的資本和運營費用;產品開發和相關臨床試驗和驗證研究中的不確定性,包括我們對於美國食品藥品監督管理局和歐盟的兒童臨床試驗的成功依賴性以及DETECt-試驗的結果可能不支持在兒童成長激素缺乏症的監管批准申請;馬克莉倫(馬西莫林)由昆士蘭大學或爲我們開發的其他產品的正在進行或計劃中的臨床前研究的結果可能不成功或可能不支持將產品推向人類臨床試驗;我們籌集資本和獲得融資以繼續我們目前計劃中的業務;我們現在嚴重依賴馬西莫林(馬西莫林)的成功和相關的外部許可安排以及成功商業化產品所需的資金和資源的持續可用性;確保擁有後期開發、營銷和分銷夥伴,其中包括我們能否在與Novo Nordisk AG終止許可協議後達成新的許可協議或類似安排;我們進入與其他製藥公司的許可、開發、製造、營銷和分銷協議的能力,並使這些協議繼續有效;保護和執行我們的專利組合和知識產權的能力;以及我們繼續在納斯達克上市我們的普通股的能力。
Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in Childhood Growth Hormone Deficiency may impact the market for macimorelin (Macrilen; Ghryvelin) in AGHD and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market.
展望性聲明涉及已知和未知的風險與不確定因素,包括但不限於:合併公司的當前和未來業務戰略;運營和績效在預期範圍內;預期未來現金流;合併公司運營環境中的本地與全球經濟情況;預期資本支出與運營成本;我們從已投放市場產品、產品研發和相關臨床試驗及驗證研究中的營業收入產生不確定性;我們正在研發的產品可能在臨床試驗中失敗或無法支持產品推進;DETECt-試驗未能達到童年生長激素缺乏症的主要終點可能影響馬西莫林(Macrilen; Ghryvelin)在生長激素成人缺乏症的市場和我們爲該產品建立的現有關係;籌集資金並獲取融資以繼續我們目前計劃的業務;我們目前對遺產Ceapro產品的主要經銷商及其客戶銷售的依賴程度加重,成功商業化我們的產品所需資金和資源的持續可用性;尋求後期開發、營銷和分銷戰略合作伙伴的能力;與其他製藥公司簽訂外部授權、研發、製造、營銷和分銷協議並保持此類協議的有效性的能力;保護和執行我們的專利組合和知識產權的能力;以及我們繼續在納斯達克資本市場上市我們的普通股的能力。
Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at and on EDGAR at www.sec.gov. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
沒有證券監管機構批准或否定此新聞稿的內容。多倫多證券交易所不對此新聞稿的充分性或準確性承擔責任。 和 www.sec.gov我們不承擔更新任何此類風險或不確定性的義務,也不會公開宣佈任何對此處所包含的任何前瞻性聲明的修訂,以反映未來的結果、事件或發展,除非受到政府機構或適用法律的要求。
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.
沒有證券監管機構已經覈准或駁回本新聞稿的內容。多倫多證券交易所對本新聞稿的充分性或準確性概不負責。
Issuer:
Gilles R. Gagnon
President & CEO
ggagnon@ceapro.com
+1 (780) 421-4555
發行人:
吉爾·加尼昂
總裁兼首席執行官
ggagnon@ceapro.com
+1 (780) 421-4555
Investor Contact:
Jenene Thomas
JTC Team
T (US): +1 (908) 824-0775
E: csci@jtcir.com
投資者聯繫人:
Jenene Thomas
JTC團隊
t(美國):+1(908) 824-0775
電子郵件:csci@jtcir.com
譯文內容由第三人軟體翻譯。